BRIEF-Solid Biosciences Receives FDA Orphan Drug Designation For Sgt-212 Dual-Route Gene Therapy

Reuters

Jan 13

BRIEF-<a href="https://laohu8.com/S/SLDB">Solid Biosciences</a> Receives FDA Orphan Drug Designation For Sgt-212 Dual-Route Gene Therapy

Jan 12 (Reuters) - Solid Biosciences Inc SLDB.O:

SOLID BIOSCIENCES RECEIVES FDA ORPHAN DRUG DESIGNATION FOR SGT-212 DUAL-ROUTE GENE THERAPY FOR THE TREATMENT OF FRIEDREICH’S ATAXIA
SOLID BIOSCIENCES- DOSING OF FIRST PARTICIPANT IN PHASE 1B FALCON TRIAL COMPLETED, INITIAL DATA EXPECTED IN H2 2026

Source text: ID:nGNXbmM6G5

Further company coverage: SLDB.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2603526997"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603526997\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603526997?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 05:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603526997","market":"us","top_or_hot":-1,"title":"BRIEF-Solid Biosciences Receives FDA Orphan Drug Designation For Sgt-212 Dual-Route Gene Therapy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/SLDB\">Solid Biosciences</a> Receives FDA Orphan Drug Designation For Sgt-212 Dual-Route Gene Therapy </title></head><body><p><span>Jan 12 (Reuters)</span><span> - </span>Solid Biosciences Inc <span>SLDB.O</span>:</p><ul><li><p>SOLID BIOSCIENCES RECEIVES FDA ORPHAN DRUG DESIGNATION FOR SGT-212 DUAL-ROUTE GENE THERAPY FOR THE TREATMENT OF FRIEDREICH’S ATAXIA</p></li><li><p>SOLID BIOSCIENCES- DOSING OF FIRST PARTICIPANT IN PHASE 1B FALCON TRIAL COMPLETED, INITIAL DATA EXPECTED IN H2 2026</p></li></ul><p>Source text: <span>ID:nGNXbmM6G5</span></p><p>Further company coverage: <span>SLDB.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Solid Biosciences Receives FDA Orphan Drug Designation For Sgt-212 Dual-Route Gene Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Solid Biosciences Receives FDA Orphan Drug Designation For Sgt-212 Dual-Route Gene Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-13 05:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/SLDB\">Solid Biosciences</a> Receives FDA Orphan Drug Designation For Sgt-212 Dual-Route Gene Therapy </title></head><body><p><span>Jan 12 (Reuters)</span><span> - </span>Solid Biosciences Inc <span>SLDB.O</span>:</p><ul><li><p>SOLID BIOSCIENCES RECEIVES FDA ORPHAN DRUG DESIGNATION FOR SGT-212 DUAL-ROUTE GENE THERAPY FOR THE TREATMENT OF FRIEDREICH’S ATAXIA</p></li><li><p>SOLID BIOSCIENCES- DOSING OF FIRST PARTICIPANT IN PHASE 1B FALCON TRIAL COMPLETED, INITIAL DATA EXPECTED IN H2 2026</p></li></ul><p>Source text: <span>ID:nGNXbmM6G5</span></p><p>Further company coverage: <span>SLDB.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SLDB","symbol_name":"Solid Biosciences","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA6JCLDJ:1","article_id":"2603526997","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603526997","pubTimestamp":1768252617,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Solid Biosciences Receives FDA Orphan Drug Designation For Sgt-212 Dual-Route Gene Therapy Jan 12 (Reuters) - Solid Biosciences Inc SLDB.O:SOLID BIOSCIENCES RECEIVES FDA ORPHAN DRUG DESIGNATION ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SLDB":"Solid Biosciences","BK4139":"生物科技"},"translate_title":"简介-Solid Biosciences获得FDA SGT-212双途径基因疗法孤儿药资格","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLDB":0.9},"content_text":"BRIEF-Solid Biosciences Receives FDA Orphan Drug Designation For Sgt-212 Dual-Route Gene Therapy Jan 12 (Reuters) - Solid Biosciences Inc SLDB.O:SOLID BIOSCIENCES RECEIVES FDA ORPHAN DRUG DESIGNATION FOR SGT-212 DUAL-ROUTE GENE THERAPY FOR THE TREATMENT OF FRIEDREICH’S ATAXIASOLID BIOSCIENCES- DOSING OF FIRST PARTICIPANT IN PHASE 1B FALCON TRIAL COMPLETED, INITIAL DATA EXPECTED IN H2 2026Source text: ID:nGNXbmM6G5Further company coverage: SLDB.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}